Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single dose, cross-over pharmacokinetic study comparing oral formulations of BNC210 in healthy male volunteers

Trial Profile

A single dose, cross-over pharmacokinetic study comparing oral formulations of BNC210 in healthy male volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Agitation; Anxiety disorders; Post-traumatic stress disorders
  • Focus Pharmacokinetics
  • Sponsors Bionomics
  • Most Recent Events

    • 05 Dec 2018 Status changed from Active not recruiting to completed.
    • 08 Aug 2018 Planned End Date changed from 2 Aug 2018 to 9 Aug 2018.
    • 19 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top